# A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis

> **NCT04285229** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 147 (actual)

## Conditions studied

- Spondyloarthritis

## Interventions

- **DRUG:** Ixekizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04285229
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-10
- **Primary completion:** 2021-03-31
- **Final completion:** 2022-03-17
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04285229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04285229, "A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04285229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*